Abstract
The chronic lymphocytic leukemia (CLL) is the most common blood cancer in adult patients. We performed a multiple treatments meta-analysis using the evidence found in reports of randomized controlled trials (RCTs) identified in the PubMed database to compare a response to available first-line treatments of CLL. Twenty three trials involving 7,507 patients were included in the analysis comparing the complete remission (CR) and the partial remission (PR) rates of different therapy options. A Bayesian framework was applied using a Markov Chain Monte-Carlo technique. Chlorambucil was considered to be the reference treatment. All the analyzed treatments ensured higher CR and PR than the reference treatment. The obtained results suggest that bendamustine has the highest probability of being the most efficacious treatment in terms of CR and PR in patients with previously untreated CLL.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this paper
Cite this paper
Molik, M., Ładyżyński, P., Foltyński, P., Wójcicki, J.M. (2015). A Multiple Treatments Meta-Analysis of a Response to the First-Line Treatment of the Chronic Lymphocytic Leukemia. In: Lacković, I., Vasic, D. (eds) 6th European Conference of the International Federation for Medical and Biological Engineering. IFMBE Proceedings, vol 45. Springer, Cham. https://doi.org/10.1007/978-3-319-11128-5_23
Download citation
DOI: https://doi.org/10.1007/978-3-319-11128-5_23
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11127-8
Online ISBN: 978-3-319-11128-5
eBook Packages: EngineeringEngineering (R0)